Cal Trainers Warned Off CBD Use in Horses

The Cannabidiol (CBD) market is growing faster than a garden weed, and as the vast roots of this multi-billion dollar industry reach further into everyday life, it’s hardly surprising that the racing industry has had to take accommodating actions.

This can be evinced in a California Horse Racing Board (CHRB) notification sent to trainers Friday, warning that use of these CBD products can lead to a positive “for CBD and/or CBD metabolites in blood and urine,” and that, because CBD is currently unclassified in California, a positive would by default result in a class 1, category A drug violation.

“My recommendation to the horsemen is do not use this product on a racehorse that is going to be subject to testing, which is basically all of them,” CHRB equine medical director Rick Arthur told the TDN. “The risk is so out of proportion to the reward that it would be foolish to use this product on a racehorse.”

Under CHRB rules, a class 1, category A violation can lead to a minimum one-year suspension or a maximum three-year suspension. It can also result in a minimum fine of $10,000 or 10% of the gross purse, or a maximum fine of $25,000 or 25% of the purse.

The Association of Racing Commissioners International (ARCI) currently classifies CBD as a lower class 3 category B penalty. The CHRB will likely begin the process of updating the state’s rules to align with the ARCI’s CBD classification early next year, but because of California’s “very cumbersome administrative law process,” the formal adoption of those rules could take another year, Arthur warned.

Until then, a CBD positive will remain a class 1, class A penalty. Still, the stewards have the authority to “modify the penalty out of any sense of fairness,” Arthur said, pointing to language pertaining to “mitigating circumstances” in the rules.

“I suspect that the ARCI has a penalty category B is a [possible] mitigating circumstance,” he added. “But that’s not up to me, that’s up to the stewards.”

Arthur declined to comment if Friday’s notification was sent as a result of any recent CBD positive finding awaiting adjudication, but he added that up to this point in California, there has been no formal complaint filed for a positive finding of either CBD or Tetrahydrocannabinol (THC), the compound in cannabis that creates a psychoactive “high.”

“This has always surprised me because marijuana is commonly used on the backside,” Arthur said.

While derived from both marijuana and industrial hemp plants, CBD is not responsible for any psychoactive effect. Nevertheless, while CBD products are required to contain less than 0.3% THC, lack of regulatory oversight means that some CBD products contain much more THC than that. The ARCI designates a CBD product with more than 0.3% THC as a class 1, category A substance.

The purported benefits from CBD use in horses include treatment of inflammation, ulcers, laminitis, colic, and decreased anxiety. However, “None of these claims are substantiated with independent, peer reviewed research in the horse,” according to a Racing Medication & Testing Consortium (RMTC) cannabidiol bulletin from last year.

Among some of the findings in published literature, CBD has been shown to help ameliorate the pain of osteoarthritis in dogs and ease anxiety in humans. One recent study out of Colorado found a potential correlation between CBD use in dogs and reduced seizure frequency.

In terms of its potential performance enhancing effects–a loaded term with all sorts of broadly applicable connotations–the U.S. Equestrian Federation (USEF) Equine Drugs and Medications Rules prohibit CBD and CBD metabolites in competition.

“CBD, both natural and synthetic forms, are likely to affect the performance of a horse due to its reported anxiolytic effects,” the federation wrote last year. Anxiolytic effects are those related to anxiety and stress reduction. “This substance is no different than legitimate therapeutics that effect mentation and behavior in horses.”

According to Mary Scollay, RMTC executive director and chief operating officer, there are any number of studies currently underway, including on horses, digging down into what medical properties CBD actually has.

“As it stands right now, there is no scientific basis for use in the horse,” said Scollay. As the scientific literature continues to pour in, “we might have to revisit the classification,” she said, but added that she wouldn’t expect any such reclassification “to change much.”

Experts point to the wild west nature of the CBD market at present, with much variability in purity, strength, and safety of these products. A recent study out of Europe found that more than two-thirds of the 14 CBD products tested contained concentrations that differed by more than 10% from the label. As such, in its bulletin the RMTC offers no recommended withdrawal times.

“Bad guidance is worse than no guidance,” said Scollay.

The CHRB notification to trainers states how CBD and its metabolites can be detectable for 72-96 hours after ingestion by the horse, though it provides no indication of dose. According to Arthur, the 72-96 hour designation comes from a study that will be ready for publication early next year.

Arthur said that he is unaware of how widely used CBD products are on the backstretch. Scollay said that when she was working as Kentucky Horse Racing Commission equine medical director, CBD products were starting to become aggressively marketed,” and I was getting lots of calls, people were asking lots of questions about it.”

Scollay warned, too, of the increasing popularity of horse bedding made from hemp plants, and the residual risk of contamination.

“The question there is of the potential for exposure, and is that sufficient to generate a positive CBD test?” Scollay said. “I have heard that at least one project has indicated that that is the case.”

“The all-natural aspect of it, some people equate that to benign,” Scollay said, of CBD products in general, “and that’s not a logical leap.”

The post Cal Trainers Warned Off CBD Use in Horses appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

AAEP Honors Regulatory Vet Dr. Mary Scollay With 2020 Distinguished Service Award

The American Association of Equine Practitioners (AAEP) honored a longtime volunteer leader within the association and strident advocate for the welfare of racehorses and the integrity of racing when presenting the 2020 Distinguished Service Award to Mary Scollay, DVM.

The Distinguished Service Award honors exemplary service to the AAEP or a similar organization to the benefit of the horse, horse industry or profession of equine veterinary medicine. Dr. Scollay was recognized Dec. 9 during the AAEP's 2020 Annual Convention & Trade Show, held virtually.

A 1984 graduate of the University of Illinois College of Veterinary Medicine, Dr. Scollay is currently serving her fourth term on the AAEP's Racing Committee, having initially joined the committee in 1997. She contributes to racing broadcasts as an On Call veterinary spokesperson and is co-author of several consequential AAEP white papers on racehorse health and welfare as well as related reference documents for equine veterinarians. Beyond her racing contributions, Dr. Scollay also serves on the AAEP's Professional Conduct & Ethics Committee, and she previously chaired the Infectious Disease Committee and served on the Equine Welfare Committee.

Dr. Scollay is executive director and COO of the Lexington, Ky.-based Racing Medication and Testing Consortium, which focuses on research, education and advocacy for science-based initiatives that promote the health and safety of racehorses and the integrity of competition. Prior to joining the RMTC in 2019, Dr. Scollay spent 11 years as the Kentucky Horse Racing Commission's first equine medical director and 13 years as senior association veterinarian at Calder Race Course and Gulfstream Park in south Florida. While in Florida, she conceptualized and developed the forerunner to The Jockey Club's Equine Injury Database, to which she has served as a veterinary consultant since its launch in 2008.

“With her unwavering philosophy that the health and welfare of the horse remains paramount above all else, Dr. Scollay has provided many years of outstanding service to the veterinary profession, steadfast dedication to the equine industry, and deep commitment to the mission of the AAEP,” said nominator Dr. Patricia Marquis.

The post AAEP Honors Regulatory Vet Dr. Mary Scollay With 2020 Distinguished Service Award appeared first on Horse Racing News | Paulick Report.

Source of original post

AAEP Honors Palmer, Scollay and New Vocations

The American Association of Equine Practitioners has presented Scott Palmer, VMD, its 2020 Sage Kester “Beyond the Call” Award. The award is named in honor of its first recipient, the late Wayne O. “Sage” Kester, DVM, and recognizes a current or former AAEP member who has made significant and long-lasting contributions to equine veterinary medicine and the community. A past president of the AAEP, Palmer worked in clinical practice as a staff surgeon and hospital director of the New Jersey Equine Clinic for 38 years. He was appointed equine medical director for the New York State Gaming Commission in 2014 and his safety reforms recommendation implemented at the state’s racetracks are credited with elevating New York racing to among the safest in the country and have served as a model for racing stakeholders in other regions.

Palmer’s contributions to racehorse safety also include current service on the Racing Medication & Testing Consortium Scientific Advisory Committee and on the Association of Racing Commissioners International Drug Testing Standards & Practices Committee and Equine Welfare & Veterinarians Committee.

“As a leader, Dr. Palmer comes to any challenge fully prepared, listens attentively to all opinions, is always willing to adjust his own position if indicated, and clearly and respectfully articulates his opinions,” said nominator Dr. Harry Werner. “These leadership qualities are very much respected by those who work with him.”

During the AAEP’s 2020 Annual Convention & Trade Show, held virtually Dec. 9, the group also honored Mary Scollay, DVM with its Distinguished Service Award. Scollay, now in her fourth term on the AAEP’s Racing Committee, is executive director and COO of the Racing Medication and Testing Consortium. She also spent 11 years as the Kentucky Horse Racing Commission’s first equine medical director and 13 years as senior association veterinarian at Calder Race Course and Gulfstream Park in south Florida. While in Florida, she conceptualized and developed the forerunner to The Jockey Club’s Equine Injury Database, to which she has served as a veterinary consultant since its launch in 2008.

“With her unwavering philosophy that the health and welfare of the horse remains paramount above all else, Dr. Scollay has provided many years of outstanding service to the veterinary profession, steadfast dedication to the equine industry, and deep commitment to the mission of the AAEP,” said nominator Dr. Patricia Marquis.

The AAEP honored New Vocations Racehorse Adoption Program, the largest racehorse adoption charity in the United States, with the 2020 Lavin Cup, recognizing a non-veterinary organization or individual that has distinguished itself through service to improve the welfare of horses.

Founded in 1992, New Vocations’ mission to rehabilitate, retrain and rehome retired racehorses has led to the placement of over 7,000 individuals, with nearly 500 retirees served by the program each year. With facilities in five states–Kentucky, New York, Ohio, Pennsylvania and Louisiana–New Vocations serves over 40 racetracks, working directly with owners and trainers in need of equine aftercare options.

“New Vocations has a longstanding commitment to the health and welfare of the equine athletes that deserve help in transitioning to a healthy and productive second career,” said co-nominators Dr. Jeff Berk and Dr. Wesley Sutter. “In every sense, they have partnered with us, the equine veterinarians who seek the same goals for our patients.”

During its annual convention and trade show, the AAEP also installed Scott Hay, DVM, president and managing shareholder of Fort Lauderdale, Florida-based racetrack practice Teigland, Franklin and Brokken DVMs, as president.

The post AAEP Honors Palmer, Scollay and New Vocations appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

The `Black Eye’ of Environmental Contamination, Part Two

(This is the second in a series we are doing on environmental contamination. Click here for part one.)

Like a Matryoshka doll of conjecture and supposition, the very real threat of environmental contamination in the horse racing industry’s testing protocols can play out like a game that becomes ever more intricate with each layer unpeeled.

In part one of this series, we looked at a growing understanding of the array of possible contaminants in the backstretch environment coupled with ever more sensitive testing methodologies.

But go deeper, and what emerges are questions surrounding things like metabolism rates and pathways of exposure, chemical stability and analytical sensitivity, burdens of proof and innocence.

So, what do some industry experts posit as possible solutions to the kinks bedeviling the current testing infrastructure?

For some, the first port of call belongs in the medication rule books–more specifically, the arcana of testing thresholds.

These thresholds are permissible amounts of a legal therapeutic medication in a given sample–designed to be an indication, regulators say, that it was administered at the proper time and at the proper dose, and that the horse was not racing under the influence of a performance-enhancing dose of something.

The Association of Racing Commissioners International (ARCI)’s “Endogenous, Dietary, or Environmental Substances Schedule” is a list of 10 substances with their associated testing thresholds. Caffeine has a threshold of 100 ng/ml in blood, for example. For morphine, it’s 30 ng/ml in urine. The Racing Medication & Testing Consortium (RMTC)’s “Controlled Therapeutic Substances Schedule” is a list of another 28 regulated medications with associated thresholds.

Nevertheless, there are all sorts of other substances of both horse and human use found frequently in the backstretch environment for which there are no such thresholds.

Because of this omission, Steve Barker, former director of the Louisiana State University Equine Medication Surveillance Laboratory, says he believes the industry needs to convene a team of experts, including pharmacologists, to establish a more sweeping and comprehensive set of testing thresholds.

This list would take into account the ubiquity of substances across the nation’s backstretches, as well as to determine levels below which they have no pharmacological effect–in other words, amounts that don’t enhance the performance of a horse.

“We need a veterinary pharmacologist review to say, ‘this is what the drug does, and yes it has the potential to be a sedative or be a stimulant–all these things, it has the potential to be–but at these levels, it does nothing,'” says Barker.

“This need not be so damaging to the integrity to racing, but it is damaging,” Barker says, adding that in some cases where thresholds are already in place, they may need to be raised to take into account the additional threat of environmental contamination.

Some experts, however, urge caution.

“It is not an unreasonable suggestion on the face of it,” says RMTC executive director and chief operating officer Mary Scollay, regarding an across-the-board look at thresholds.

But Scollay warns that the industry needs to be careful not to adopt more permissive rules that result in the sport’s integrity being even further eroded.

Indeed, there are various reasons why the RMTC hasn’t already established testing thresholds for medications, permitted and otherwise, including how the use of a particular drug in close proximity to a race may be deemed ethically objectionable.

“You’ve got to think about the other people in the race,” says Scollay. “Can they legitimately feel like their horse had a fair shot and was not at a chemical disadvantage?”

A broader snag appears to concern the term “performance enhancing”–a phrase tossed around like a tennis ball, but one that can have a kaleidoscopic set of interpretations and permutations.

“When you have a horse that wins by half a nose, and if that horse ends up having some sort of a drug in its system, how can you say with certainty that there was no performance-effecting thing going on?” says a director of a U.S. laboratory, who asked to remain anonymous due to their company’s involvement in ongoing litigation.

“Performance is more than about speed, right?” says the director. “It’s about focus. It’s about determination. It’s about drive. It’s about a whole bunch of things.”

“No one size fits all”

University of Kentucky professor Scott Stanley agrees that the nailing down of thresholds can be a complicated task. He pointed to scopolamine–a substance that can appear in jimson weed, a potential feed contaminant made infamous by Justify’s positive test following his 2018 GI Santa Anita Derby win.

According to Stanley, not only can scopolamine appear at different levels in the jimson weed’s stem, leaf or seed, but these levels can also be altered by the conditions in which the plant grew, like a bad drought season.

“So now I’m supposed to establish a threshold for potential exposure that may shift and change on the fly, depending on the season and the environment, and whether the horse was exposed to this over several days or a single time,” Stanley says.

“Not one size fits all,” he says, adding that the determination of legitimate instances of environmental contamination is a similar scientific minefield. “We don’t necessarily know how, when and why the contamination happens. And it’s rarely the same every time.”

The problem, says Stanley, is racing’s current “hardline regulations, which are appropriate 99% of the time,” he says. “We need to have more modernized rules that can address situations like this.”

Over the past few years, many regulators have modified their rules to better take into account the threat of environmental contamination. In recent years, the Kentucky Horse Racing Commission (KHRC) altered its absolute-insurer rule to allow trainers with a medication positive to provide rebuttal during hearings, for example.

But as it currently stands, a positive finding almost always triggers a formal regulatory process that critics argue too often ends in unnecessary penalties when environmental contamination is to blame. On top of that are the not-inconsiderable costs that aggrieved connections can amass if they choose to legally defend their reputations.

Which is why Stanley suggests that a non-prosecutorial “initial review” first take place before any regulatory action occurs, if indeed environmental contamination appears a genuine possibility.

An initial review–conducted by an independent panel of experts with no skin in the outcome–would afford regulators a needed window with which to investigate cases that defy simple explanation and without the regulatory clock ticking.

Back in 2013, 48 California-based horses tested positive for Zilpaterol–then a Class 3 medication that is also used as a supplement for weight gain in livestock. The contamination was traced back to a batch of contaminated sweet feeds.

Zilpaterol is the “perfect example” of the need for such a review system, Stanley says. “We would never have considered Zilpaterol when it happened as a contamination exposure issue.”

A non-prosecutorial initial investigation would also afford regulators the opportunity to determine whether a positive is intentional or inadvertent, and thus give them avenues to embark upon formal regulatory proceedings or dismiss the case altogether without penalty if environmental contamination is proven.

If the preponderance of evidence supports that the positive finding did not affect the horse’s performance, and that it was outside the trainer’s control, “then the horse shouldn’t be disqualified,” Stanley says.

“There’s no room for error”

There are other ways to modernize the regulatory framework, especially when it comes to detection limits and screening limits for which there can be much variability between laboratories, say experts.

A detection limit is the lowest level at which a laboratory can detect with confidence a certain substance. That different laboratories often have different detection limits for substances is a problem primarily for those without established testing thresholds–in other words, the “non-threshold” substances.

In a nutshell, what this means is that one laboratory might be able to accurately detect a substance at a lower level than another, making the playing field less than fair for trainers across the country, say experts.

A similarly problematic paradigm exists when it comes to screening limits, typically higher than the detection limit, and what is in essence an established cut-off limit for detection.

Screening limits differ from testing thresholds in that they aren’t permissible amounts of a regulated drug–rather, as Scollay puts it, they are levels that trigger further analysis.

And while the RMTC has recommended screening limits for certain substances–less than a dozen, says Scollay–in an effort to “harmonize” practices across different laboratories, “to a large extent, it’s unknown” just how much variability in testing for non-threshold substances there is, she admits.

“They screen for so many substances,” says Scollay. “Until a certain substance gets on our radar screen and we have a discussion, we don’t really know how the labs respond.”

On a more fundamental level, trainers, regulators and scientists emphasize the need for a wholesale revision of management practices across the nation’s backstretches and testing areas. “Equine environments aren’t pristine and never will be, but we must do something,” says Barker.

Some look to the trainers to make their barns as contaminant-free as possible, ensuring that all medications are handled cleanly and professionally, for example, and that staff don’t urinate in the stalls. “If you can’t housebreak the help, you probably shouldn’t have a trainer’s license,” says Scollay.

But many horsemen are in turn highly critical of the tracks themselves and argue that facilities across the nation don’t take nearly enough rigorous care to ensure the ship-in stalls, the receiving barns, and the test areas are clean.

“I have on occasion complained to management because you ship into some stalls on race day and you’ll find manure from the day before or bandages that haven’t been thrown in the trash,” says trainer Graham Motion. “In many countries it wouldn’t be acceptable.”

Indeed, in the United Kingdom, horses typically are stabled at the racetrack only for the day of the race. When they leave, the racetrack must clean the empty boxes to one of two levels of cleanliness, or else face a possible fine. A similar punitive set of standards in the U.S., says Motion and others, could help fix a glaring problem.

“The levels we’re being tested at nowadays are so minuscule, there’s no room for error here,” Motion says. “Like we’re being held to high standards as trainers, which is a good thing, so should they be held to high standards as well.”

 

The post The `Black Eye’ of Environmental Contamination, Part Two appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Verified by MonsterInsights